T. Tamura et al., UP-REGULATION OF INTERFERON-ALPHA RECEPTOR EXPRESSION IN HYDROXYUREA-TREATED LEUKEMIA-CELL LINES, Journal of investigative medicine, 45(4), 1997, pp. 160-167
Citations number
37
Categorie Soggetti
Medicine, Research & Experimental","Medicine, General & Internal
Background: Interferon-alpha (IFN-alpha) shows its antitumor effect th
rough binding to specific cell surface receptors, A DNA synthesis inhi
bitor, hydroxyurea (HU), has been successfully combined with IFN-alpha
to improve the efficiency of IFN therapy for chronic myelogenous leuk
emia (CML), To understand the mechanism of this combination effect, ex
pression of IFN-alpha or receptors on the CML cell line, K562, was stu
died before and after treatment with HU. Methods: Cells were treated,v
ith HU at a dose of 0, 0.1, 0.2, or 0.4 mmol/L for 48 hours. Binding a
ssays were performed using I-125-labeled IFN-alpha at 4 degrees C, Cel
l cycle analysis was carried out using flow cytometer following staini
ng cellular DNA with propidium iodide, Northern blot analysis was perf
ormed to evaluate the inducibility of interferon regulatory factor-1 (
IRF-1) gene expression by IFN-alpha. Results: Hydroxyurea-treated cell
s showed a dose- and time-dependent increase in binding of I-125-label
ed IFN-alpha (maximal 2.5-fold), The increase of binding was caused by
an increase in the number of binding sites with a constant receptor a
ffinity, Similar results were obtained in the Burkitt's lymphoma cell
line, Daudi, Cell cycle analyses suggested that upregulation of the IF
N receptor may have occurred as a result of the alteration in the cell
cycle distribution, Furthermore, IFN-alpha induction of the IFN-induc
ible gene IRF-1 mRNA in HU-treated K562 cells was 2-fold higher than t
hat in untreated cells. Conclusions: Thus, HU may have an ability to e
nhance the response to IFN-alpha probably because of its ability to up
regulate the IFN-alpha receptors, suggesting that this may be involved
in the mechanism of effective combination therapy of IFN-alpha with H
U.